ArticleDiscover oncology2025
Impact of lymph node yield on survival of patients with metastatic esophageal cancer: a population-based retrospective study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer is the seventh most common cancer worldwide, and its related mortality remains high. The association between lymph node yield and survival outcomes in patients with distant lymph node metastatic esophageal cancer has not been well studied. This study aimed to investigate the impact of LNY on the survival of patients with metastatic esophageal cancer and to identify prognostic factors affecting survival.
methodsA total of 825 patients with metastatic esophageal cancer who underwent primary tumor resection were identified from the Surveillance, Epidemiology, and End Results database between 2000 and 2021. Survival curves were plotted using the Kaplan-Meier method and compared with the log-rank test. Propensity score matching was used to balance differences between groups. Univariate and multivariate Cox proportional hazards regression models were used to analyze prognostic factors.
resultsAmong the 825 patients included in this study, at least 6 LNYs were found to be beneficial for survival outcomes in the majority of mEC patients. Before propensity matching, the OS and CSS of the LNY > 6 group were significantly better than those of the LNY ≤ 6 group (median OS was 22.32 months and 13.3 months, respectively, P < 0.05). After propensity matching, the survival outcomes of the LNY > 6 group were still better than those of the LNY ≤ 6 group. Multivariate Cox regression analysis showed that age, race, pathological grade, and specific histological types were independent risk factors for OS. Subgroup analysis showed that patients with LNY > 6 benefited in most subgroups.
conclusionsThis study shows that the number of LNY is significantly associated with survival in patients with distant metastatic esophageal cancer, and adequate lymph node dissection may have association with improved survival. This finding provides an important basis for clinical decision-making and the design of future clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.